<SEC-DOCUMENT>0001193125-26-276056.txt : 20260618
<SEC-HEADER>0001193125-26-276056.hdr.sgml : 20260618
<ACCEPTANCE-DATETIME>20260618170016
ACCESSION NUMBER:		0001193125-26-276056
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260616
FILED AS OF DATE:		20260618
DATE AS OF CHANGE:		20260618

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Allen Andrew R
		CENTRAL INDEX KEY:			0001374539
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39856
		FILM NUMBER:		261103823

	MAIL ADDRESS:	
		STREET 1:		2525 28TH STREET
		STREET 2:		SUITE 200
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cullinan Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001789972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813879991
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE MAIN STREET
		STREET 2:		SUITE 1350
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-410-4650

	MAIL ADDRESS:	
		STREET 1:		ONE MAIN STREET
		STREET 2:		SUITE 1350
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Oncology, Inc.
		DATE OF NAME CHANGE:	20210225

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Management, Inc.
		DATE OF NAME CHANGE:	20210107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cullinan Oncology, LLC
		DATE OF NAME CHANGE:	20191001
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-06-16</periodOfReport>

    <issuer>
        <issuerCik>0001789972</issuerCik>
        <issuerName>Cullinan Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>CGEM</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001374539</rptOwnerCik>
            <rptOwnerName>Allen Andrew R</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O CULLINAN THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>ONE MAIN STREET, SUITE 1350</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>13.55</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2026-06-16</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>21781</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2026-06-16</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>21781</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>21781</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The option represents a right to purchase a total of 21,781 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jacquelyn Sumer, Attorney-in-Fact</signatureName>
        <signatureDate>2026-06-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
